Watson V, McCartan N, Krucien N, Abu V, Ikenwilo D, Emberton M, Ahmed HU. Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study. J Urol. 2020 Aug;204(2):273-80. doi: 10.1097/JU.0000000000000754
Fischer A, Zimovetz E, Ling C, Esser D, Shoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017 Nov;16(11):1147-54. doi: 10.1016/j.autrev.2017.09.010
Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia and lobular and ductal carcinoma in situ. Cancer Prev Res. 2017 Aug;10(8):434-41. doi: 10.1158/1940-6207.CAPR-17-0100
Ara R, Basarir H, Ward SE. Principles of health economic evaluations of lipid-lowering strategies. Curr Opin Lipidology. 2012 Aug;23(4):271-81. doi: 10.1097/MOL.0b013e32835423d9
Rosen RC, Wincze J, Mollen MD, Gondek K, McLeod LD, Fisher WA. Responsiveness and minimum important differences for the erection quality scale. J Urol. 2007 Nov 1;178(5):2076-81.
Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2004 Dec;172(6 Pt 1):2321-5. doi: 10.1097/01.ju.0000140957.31325.7f
Yang BK, Young MD, Calingaert B, Albala DM, Vieweg J, Murphy BC, Dahm P. Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. J Urol. 2004 Jul 1;172(1):264-8.
Vitolins MZ, Anthony M, Burke GL. Soy protein isoflavones, lipids and arterial disease. Curr Opin Lipidology. 2001 Aug;12(4):433-7.
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000 Feb 1;163(2):460-3.